CA2082948A1 - Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4 - Google Patents

Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4

Info

Publication number
CA2082948A1
CA2082948A1 CA2082948A CA2082948A CA2082948A1 CA 2082948 A1 CA2082948 A1 CA 2082948A1 CA 2082948 A CA2082948 A CA 2082948A CA 2082948 A CA2082948 A CA 2082948A CA 2082948 A1 CA2082948 A1 CA 2082948A1
Authority
CA
Canada
Prior art keywords
antibodies
relating
receptor binding
immunogenic peptides
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2082948A
Other languages
English (en)
Other versions
CA2082948C (fr
Inventor
Joseph G. Sodroski
William A. Haseltine
Udy Olshevsky
Eirik Helseth
Craig D. Furman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2082948A1 publication Critical patent/CA2082948A1/fr
Application granted granted Critical
Publication of CA2082948C publication Critical patent/CA2082948C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention se rapporte à des peptides immunogènes contenant des résidus d'acides aminés qui définissent un site de liaison avec un récepteur de molécules CD4, à des anticorps dirigés contre ces peptides, à des procédés permettant de réduire la capacité d'une protéine env gp120 à se lier à des molécules CD4, ainsi qu'à des procédés thérapeutiques et prophylactiques utilisant ces anticorps et ces peptides.
CA002082948A 1990-05-16 1991-05-16 Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4 Expired - Fee Related CA2082948C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52463290A 1990-05-16 1990-05-16
US524,632 1990-05-16
US66907291A 1991-03-14 1991-03-14
US669,072 1991-03-14
PCT/US1991/003472 WO1991017764A1 (fr) 1990-05-16 1991-05-16 Peptides immunogenes, anticorps et utilisations de ceux-ci en rapport avec la liaison du recepteur de molecules cd4

Publications (2)

Publication Number Publication Date
CA2082948A1 true CA2082948A1 (fr) 1991-11-17
CA2082948C CA2082948C (fr) 2000-07-11

Family

ID=27061560

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002082948A Expired - Fee Related CA2082948C (fr) 1990-05-16 1991-05-16 Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4

Country Status (7)

Country Link
US (2) US5817316A (fr)
EP (1) EP0651818B1 (fr)
JP (1) JPH05507491A (fr)
AT (1) ATE175446T1 (fr)
CA (1) CA2082948C (fr)
DE (1) DE69130741T2 (fr)
WO (1) WO1991017764A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2094713A1 (fr) * 1990-10-26 1992-04-27 Shermaine A. Tilley Methode de neutralisation des anticorps monoclonaux humains specifiques a la boucle v3 et au site de liaison des lymphocytes cd-4 du vih-1 gp120
JPH05262662A (ja) * 1991-07-15 1993-10-12 Calpis Food Ind Co Ltd:The Ｈｉｖ重感染防止剤、抗イディオタイプ抗体作製用抗原及び抗イディオタイプ抗体の製造法
US5665569A (en) * 1991-08-22 1997-09-09 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
EP0581353A1 (fr) * 1992-07-03 1994-02-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Anticorps monoclonaux dirigés contre HIV-1 gp120, lignées cellulaires les produisant et structures epitopiques correspondantes
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
WO1999024465A1 (fr) 1997-11-10 1999-05-20 Dana-Farber Cancer Institute Glycoproteines d'enveloppe de lentivirus de primate stabilisees
US6908617B1 (en) 1997-11-10 2005-06-21 Dana-Farber Cancer Institute, Inc. Glycosylated modified primate lentivirus envelope polypeptides
US6679851B2 (en) * 1998-09-01 2004-01-20 Senorx, Inc. Tissue accessing and anchoring device and method
US7585839B2 (en) * 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
US7250397B2 (en) * 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
WO2001083535A2 (fr) * 2000-05-02 2001-11-08 Simon Fraser University Peptides pouvant etre utilises en tant que vaccin et/ou traitement contre l'infection par hiv
WO2002056831A2 (fr) * 2000-12-27 2002-07-25 Dana-Farber Cancer Institute, Inc. Proteoliposomes immunogenes et applications de ceux-ci
EP1456382B1 (fr) 2001-03-22 2007-08-08 The United States of America, represented by the Secretary, Department of Health and Human Services Cyanovirines resistant a la glycosylation et conjugues, compositions, acides nucleiques, vecteurs, cellules hotes, associes, et procedes d'obtention et d'utilisation des cyanovirines non glycosylees
AU2003299489B2 (en) * 2002-05-10 2009-01-15 The Henry M Jackson Foundation For The Advancement Of Military Medicine, Inc Interacting site for gp41 on gp120 of HIV-1
JP3849584B2 (ja) * 2002-06-07 2006-11-22 トヨタ自動車株式会社 蒸発燃料処理装置
WO2004110384A2 (fr) * 2003-06-12 2004-12-23 Vaxgen, Inc. Glycoproteines d'enveloppe du vih-1 a structure disulfure inhabituelle
WO2005029078A1 (fr) * 2003-09-17 2005-03-31 Guava Technologies, Inc. Compositions et procedes pour l'analyse d'analytes cibles
AU2007207544A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
JP2010533690A (ja) * 2007-07-15 2010-10-28 ジーランド・ファーマ・ア／エス ペプチドギャップ結合モジュレーター
CN102639149A (zh) 2009-03-05 2012-08-15 哈佛学院董事会 分泌的aP2及其抑制方法
CA2793959C (fr) 2010-03-25 2019-06-04 Oregon Health & Science University Glycoproteines du cmv et vecteurs recombines
EP2492279A1 (fr) * 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Procédé de sélection rapide d'immunogène par expression à la surface du lentivirus.
EP2691530B1 (fr) 2011-06-10 2018-03-07 Oregon Health & Science University Glycoprotéines de cmv et vecteurs recombinants cmv
WO2013006688A2 (fr) * 2011-07-05 2013-01-10 Duke University Immunogènes gp120 à extrémité n-terminale délétée
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2013052095A2 (fr) 2011-10-03 2013-04-11 Duke University Vaccin
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (fr) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Trimères de glycoprotéines d'enveloppe du vih -1 soluble
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
MX2017013807A (es) 2015-04-30 2018-03-15 Harvard College Anticuerpos anti-proteina de union al lipido de adipocito humana (ap2) y agente de union al antigeno para tratar trastornos metabolicos.
CA3066733A1 (fr) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Procede d'identification de composes utiles pour traiter une lipogenese deregulee, le diabete et autres troubles apparentes
US11440948B2 (en) 2019-01-28 2022-09-13 Xyphos Biosciences Inc. Modified non-natural NKG2D ligands that selectively deliver attached heterologous molecules to non-natural NKG2D receptors on car-cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3855869T2 (de) * 1987-02-20 1997-10-02 Genentech Inc Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV

Also Published As

Publication number Publication date
DE69130741T2 (de) 1999-07-29
ATE175446T1 (de) 1999-01-15
WO1991017764A1 (fr) 1991-11-28
US5817316A (en) 1998-10-06
US5858366A (en) 1999-01-12
EP0651818B1 (fr) 1999-01-07
CA2082948C (fr) 2000-07-11
EP0651818A4 (fr) 1993-08-09
JPH05507491A (ja) 1993-10-28
DE69130741D1 (de) 1999-02-18
EP0651818A1 (fr) 1995-05-10

Similar Documents

Publication Publication Date Title
CA2082948A1 (fr) Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4
CA2164818A1 (fr) Peptides synthetiques en tandem, vaccins contre le vih-1
EP0339504A3 (fr) Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
WO1991004273A3 (fr) Nouveaux peptides associes a la region de liaison cd4 de la gp120 et leur mode d'emploi
CA2363947A1 (fr) Peptides, antigenes du vih, compositions de vaccins afferentes, trousse de dosage immunologique et methode de detection d'anticorps induits par le vih
CA2143163A1 (fr) Peptides derives d'un retrovirus du groupe vih et leur utilisation
EP0554401A4 (en) Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
WO1988009181A3 (fr) Anticorps monoclonaux neutralisant le hiv-1
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
EP0328403A3 (fr) Peptides synthétiques relatifs à la protéine HIV-GP120-env. et leur application
EP0284587A3 (fr) Antigènes peptides synthétiques pour la détection d'infections de HIV-1
CA2091263A1 (fr) Peptides utilises pour la vaccination et l'induction d'anticorps neutralisants contre le virus de l'immunodeficience humaine
CA2258494A1 (fr) Olypeptides capables de former des structures de liaison a l'antigene avec une specificite pour les antigenes de rhesus d, adn les codant et procede pour leur preparation et leur utilisation
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
EP0853662A4 (fr) Nouveau clone proviral du virus de l'immunodeficience humaine de type 2 (hiv-2) a possibilite de replication, appele hiv-2kr
EP0344006A3 (fr) Peptides bloquant la liaison de HIV-1 vers CD4 du récepteur de protéine
CA2129747A1 (fr) Peptide pour diagnostiquer l'infection a t. cruzi et pour immuniser contre cet agent
CA2181590A1 (fr) Peptomeres a immunogenicite accrue
EP0478689A4 (en) Human monoclonal antibodies to hiv-1 mn? gp 120
AU641736B2 (en) Delivery of agents
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
CA2086509A1 (fr) Nouveau variant gp160 non-clivable, soluble, de forme hybride
ZA892907B (en) Peptides derived from human immunodeficiency virus-1 gp160
EP0385909A3 (fr) Kit ou composition pour la prévention ou le traitement des infections par HIV-1

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed